Raybow is happy to announce that on Monday March 2nd we restored our Chinese R&D and manufacturing sites to full capacity as all of our employees we able to return, healthy and safe from their various quarantine locations. The Raybow team is fully committed to catch up quickly from the unexpected 18 day shut down due to Covid-19 isolation. Raybow is now running our 5 facilities 24/7 to achieve this aim.
No medicines were delayed as contingency stock has buffered the 18-day delay. Our operations in USA and Europe were not affected by Covid-19 at the time of this writing. We continue to monitor the situation globally.